Search research articles
Contact Us
Filters
Showing results (1-10 of 245) with videos related to
Page
of 25
Sort By:
Breast Cancer Research and Treatment
|
February 14, 2015
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
Fabrice André, Javier Cortés
Bulletin Du Cancer
|
June 21, 2011
[Her2 a paradigm for targeted therapy]
Hélène Marijon, Fabrice André
La Revue Du Praticien
|
March 4, 2014
[Supervision after breast cancer treatment]
Shanna Rajpar, Fabrice André
Cancers
|
April 30, 2021
Tribbles Pseudokinase 3 Regulation and Contribution to Cancer
Bojana Stefanovska, Fabrice André, Olivia Fromigué
Nature Reviews. Clinical Oncology
|
June 17, 2010
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use
Charles Ferté, Fabrice André, Jean-Charles Soria
Breast (Edinburgh, Scotland)
|
August 5, 2015
What to expect from high throughput genomics in metastatic breast cancers?
Concetta Elisa Onesti, Cécile Vicier, Fabrice André
BMC Medicine
|
June 11, 2015
Targeted therapies for ER+/HER2- metastatic breast cancer
Mutsuko Yamamoto-Ibusuki, Monica Arnedos, Fabrice André
Expert Opinion on Biological Therapy
|
June 15, 2005
The potential of exosomes in immunotherapy
Nathalie Chaput, Julien Taïeb, Fabrice André, et al.
Critical Reviews in Oncology/Hematology
|
August 6, 2010
Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation
Mario Campone, Philippe Juin, Fabrice André, et al.
Current Opinion in Genetics & Development
|
March 4, 2014
Genomes in the clinic: the Gustave Roussy Cancer Center experience
Ludovic Lacroix, Amelie Boichard, Fabrice André, et al.
Page
of 25
Search research articles
Search
Showing results (1-10 of 245) with videos related to
Sort By:
Page
of 25
Breast Cancer Research and Treatment
|
February 14, 2015
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
Fabrice André, Javier Cortés
Bulletin Du Cancer
|
June 21, 2011
[Her2 a paradigm for targeted therapy]
Hélène Marijon, Fabrice André
La Revue Du Praticien
|
March 4, 2014
[Supervision after breast cancer treatment]
Shanna Rajpar, Fabrice André
Cancers
|
April 30, 2021
Tribbles Pseudokinase 3 Regulation and Contribution to Cancer
Bojana Stefanovska, Fabrice André, Olivia Fromigué
Nature Reviews. Clinical Oncology
|
June 17, 2010
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use
Charles Ferté, Fabrice André, Jean-Charles Soria
Breast (Edinburgh, Scotland)
|
August 5, 2015
What to expect from high throughput genomics in metastatic breast cancers?
Concetta Elisa Onesti, Cécile Vicier, Fabrice André
BMC Medicine
|
June 11, 2015
Targeted therapies for ER+/HER2- metastatic breast cancer
Mutsuko Yamamoto-Ibusuki, Monica Arnedos, Fabrice André
Expert Opinion on Biological Therapy
|
June 15, 2005
The potential of exosomes in immunotherapy
Nathalie Chaput, Julien Taïeb, Fabrice André, et al.
Critical Reviews in Oncology/Hematology
|
August 6, 2010
Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation
Mario Campone, Philippe Juin, Fabrice André, et al.
Current Opinion in Genetics & Development
|
March 4, 2014
Genomes in the clinic: the Gustave Roussy Cancer Center experience
Ludovic Lacroix, Amelie Boichard, Fabrice André, et al.
Page
of 25